Search results for " Severity"

showing 10 items of 284 documents

Drug‐refractory myasthenia gravis: Clinical characteristics, treatments, and outcome

2022

[Objective] To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment.

Maleprogressive multifocal leukoencepdiarrheacholinergic receptorplasma exchangemiddle agedadultimmunologic factornauseaanemiahypertrichosisageddrug withdrawaldiabetes mellitusdisease severityTRIALsafetycorticosteroidhypertensionImmunologyMiastenia gravismethotrexateArticlebulbar paralysispancytopeniaMuscular DiseasescompulsionMyasthenia Gravischolinesterase inhibitorcross-sectional studyHumansImmunologic FactorshumanRITUXIMABarthralgiaNeurologíaMalalties muscularsAgedRetrospective Studiesmyasthenia gravisleukopeniaabdominal painDrug testingmajor clinical studyCross-Sectional StudiesDrug side effectscyclophosphamideobservational studyNeurology (clinical)immunoglobulinFEATURESefficacyclinical outcomeelectrophysiological procedurescomputer assisted tomographyDOUBLE-BLINDTratamiento médicorituximabOutcome Assessment Health CareImmunologiamuscle specific tyrosine kinaseRegistriestacrolimusazathioprineMedicamentoGeneral Neurosciencenephrotoxicitygeneral condition deteriorationhyperplasiatrialMiddle Agedliver toxicitydrug toxicityunclassified drugfemaleEfectes secundaris dels medicamentsSAFETYFemaledouble-blindheadacheblindnessAdultAssaigs clínics de medicamentsmalefeaturesfollow uppneumoniacyclosporinemycophenolate mofetilprotein tyrosine kinaseimmunosuppressive agentallergyalopeciaEFFICACYclinical featureosteopeniaSpainprednisonehyperglycemiaautoantibodyFollow-Up Studies
researchProduct

The Role of Nutritional Lifestyle and Physical Activity in Multiple Sclerosis Pathogenesis and Management: A Narrative Review

2021

Studies on the role of nutritional factors and physical activity (PA) in the pathogenesis of multiple sclerosis (MS) go back a long time. Despite the intrinsic difficulty of studying their positive or negative role in MS, the interest of researchers on these topics increased during the last few decades, since the role of diet has been investigated with the perspective of the association with disease-modifying drugs (DMD). The association of DMD, diets, and PA might have an additive effect in modifying disease severity. Among the various diets investigated (low-carbohydrate, gluten-free, Mediterranean, low-fat, fasting-mimicking, and Western diets) only low-carbohydrate, Mediterranean, and f…

Mediterranean dietlow carbohydrate dietPhysical activityPhysiologyphysical activityReviewlow-fat dietmultiple sclerosisDisease coursePathogenesisDisease severitygluten-free dietMediterranean dietWestern dietmedicineAnimalsHumansNutritional Physiological PhenomenaTX341-641Western dietExerciseLife StyleNutrition and Dieteticsbusiness.industryNutrition. Foods and food supplyMultiple sclerosisPatient Acuitymedicine.diseasefasting-mimicking dietNarrative reviewSettore MED/26 - NeurologiaDiet HealthybusinessFood Sciencenutritional lifestyles
researchProduct

Visceral leishmaniasis, hypertriglyceridemia and secondary hemophagocytic lymphohistiocytosis

2016

cytokines, an upregulation of adhesion molecules and MHC I and II molecules on mono/macrophages, and an expansion of inflammatory monocytes. This exaggerated inflammatory response is responsible for necrosis and organ failure and results in uncontrolled proliferation and phagocytic activity of histiocytes [2]. Hypertriglyceridemia (fasting, greater than or equal to 265 mg/100 ml) is one of the current diagnostic criteria for HLH [2]. Several studies link hypertriglyceridemia to inhibition of lipoprotein lipase (LPL) by tumor necrosis factor-α (TNF-α), and TNF-α is a powerful autocrine and paracrine regulator of adipose tissue [3]. Indeed, many different sources of intense and prolonged T-ly…

Microbiology (medical); Infectious Diseases0301 basic medicineMicrobiology (medical)Secondary Hemophagocytic LymphohistiocytosisNecrosisSettore MED/17 - Malattie Infettive030106 microbiologyAdipose tissueTriglycerideSeverityLymphohistiocytosis Hemophagocytic03 medical and health sciences0302 clinical medicinemedicineHumansMacrophage030212 general & internal medicineVisceral leishmaniasisHypertriglyceridemiaLipoprotein lipasebusiness.industryAnemia; Severity; Triglyceride; Visceral leishmaniasisHypertriglyceridemiaAnemiaGeneral Medicinemedicine.diseaseInfectious DiseasesVisceral leishmaniasisImmunologyLeishmaniasis VisceralTumor necrosis factor alphamedicine.symptombusinessInfection
researchProduct

Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.

2006

Variation in major histocompatibility complex genes on chromosome 6p21.3, specifically the human leukocyte antigen HLA-DR2 or DRB1*1501-DQB1*0602 extended haplotype, confers risk for multiple sclerosis (MS). Previous studies of DRB1 variation and both MS susceptibility and phenotypic expression have lacked statistical power to detect modest genotypic influences, and have demonstrated conflicting results. Results derived from analyses of 1339 MS families indicate DRB1 variation influences MS susceptibility in a complex manner. DRB1*15 was strongly associated in families (P=7.8x10(-31)), and a dominant DRB1*15 dose effect was confirmed (OR=7.5, 95% CI=4.4-13.0, P<0.0001). A modest dose effect…

Models MolecularMaleSequence Homologyimmune system diseasesModelsRisk FactorsDatabases GeneticAdult Alleles Amino Acid Sequence Databases; Genetic Female Genetic Variation Genotype HLA-DR Antigens; chemistry/genetics HLA-DRB1 Chains Humans Male Middle Aged Models; Molecular Molecular Sequence Data Multiple Sclerosis; Chronic Progressive; genetics/immunology Multiple Sclerosis; genetics/immunology Phenotype Risk Factors Sequence Homology; Amino Acidskin and connective tissue diseasesHLA-DRB1Genetics (clinical)GeneticsGeneral MedicineMultiple Sclerosis Chronic ProgressiveMiddle AgedAmino AcidChronic ProgressivePhenotypeFemalemusculoskeletal diseasesAdultMultiple SclerosisGenotypeMolecular Sequence DataLocus (genetics)Human leukocyte antigenBiologyDatabases. Alleles phenotype heterogeneity human leukocyte antigens age of onset chromosomes genes genotype haplotypesmultiple sclerosis relapsing-remitting genetics disability primary progressive multiple sclerosis hla-drb1 gene illness length severity of illnessGeneticGenetic variationGeneticsmedicineHumansAmino Acid SequenceAlleleMolecular BiologyAllelesSequence Homology Amino AcidMultiple sclerosisHaplotypeGenetic VariationMolecularHLA-DR Antigensmedicine.diseasegenetics/immunologychemistry/geneticsImmunologyAge of onsetHLA-DRB1 Chains
researchProduct

Role of Multiple Vitamin D-Related Polymorphisms in Multiple Sclerosis Severity: Preliminary Findings

2022

Background: Multiple Sclerosis (MS) is a multifactorial disease whose pathogenesis is the result of interaction among genetic, epigenetic, and environmental factors. Among these, a role for vitamin D hypovitaminosis has emerged in recent decades. Vitamin D levels are influenced by both environmental and genetic factors. Single nucleotide polymorphisms (SNPs) in genes codifying for molecules involved in vitamin D metabolism have been associated with an increased risk of developing MS. However, few studies assessed the association of such SNPs with the severity of the disease. The aim of this observational study was to evaluate the potential association among vitamin D status, MS severity, an…

Multiple SclerosisseveritySNPMSVitaminsGeneticsgenetic; prognosis; severity; SNP; MSCholestanetriol 26-MonooxygenaseHumansprognosisgeneticVitamin DCytochrome P450 Family 2Vitamin D3 24-HydroxylaseGenetics (clinical)Genes
researchProduct

Prevalence and severity of anaemia in patients with type 2 diabetic nephropathy and different degrees of chronic renal insufficiency.

2007

&lt;i&gt;Background/Aim:&lt;/i&gt; Type 2 diabetes mellitus is the single most common cause of chronic kidney disease (CKD); however its real impact on renal anaemia has not been established. The aim of this study was to evaluate whether onset, severity, and prevalence of anaemia during the course of CKD is different between type 2 diabetic and non-diabetic patients. &lt;i&gt;Methods:&lt;/i&gt; We enrolled 281 patients with: (1) type 2 diabetes and no CKD (n = 75); (2) type 2 diabetes plus CKD (n = 106), and (3) CKD without type 2 diabetes (n = 100). According to K/DOQI guidelines, the patients with renal insufficiency (i.e., those with a glomerular filtration rate &lt;60 ml/min) were subgr…

NephrologyMaleglomerulus filtration rateType 2 diabetesurologic and male genital diseasesGastroenterologySeverity of Illness Indexadult; aged; anemia; article; chronic kidney failure; comparative study; controlled study; creatinine clearance; diabetic nephropathy; disease course; disease severity; female; glomerulus filtration rate; hemoglobin blood level; human; kidney failure; kidney function; major clinical study; male; non insulin dependent diabetes mellitus; practice guideline; prevalence; priority journal; risk assessment; Aged; Anemia; Creatinine; Diabetes Mellitus Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Hemoglobins; Humans; Kidney Failure Chronic; Male; Middle Aged; Prevalence; Severity of Illness Index; Sex DistributionKidney FailureDiabetic nephropathychemistry.chemical_compoundHemoglobinsChronic kidney diseasecreatinine clearancePrevalenceDiabetic NephropathiesChronickidney functioncomparative studynon insulin dependent diabetes mellitusadultdisease coursearticlerisk assessmentAnemiaGeneral Medicinechronic kidney failureMiddle Agedpriority journalNephrologyCreatininedisease severityFemaleType 2Glomerular Filtration Ratemedicine.medical_specialtyAnaemia diabetes mellitus; Chronic kidney disease diabetes mellitus; Type 2 diabetes mellitus anaemiaRenal functionAnaemiaDiabetes mellitusInternal medicineType 2 diabetes mellitusDiabetes MellitusmedicineHumanscontrolled studyhumanSex DistributionAgedSettore MED/14 - NefrologiaCreatininehemoglobin blood levelbusiness.industrydiabetic nephropathypractice guidelineType 2 Diabetes Mellitusmedicine.diseasemajor clinical studySurgerychemistryDiabetes Mellitus Type 2Kidney Failure ChronicbusinessKidney disease
researchProduct

Metacognition and emotion regulation as treatment targets in binge eating disorder: a network analysis study

2021

Abstract Background This study aims to examine the underlying associations between eating, affective and metacognitive symptoms in patients with binge eating disorder (BED) through network analysis (NA) in order to identify key variables that may be considered the target for psychotherapeutic interventions. Methods A total of 155 patients with BED completed measures of eating psychopathology, affective symptoms, emotion regulation and metacognition. A cross-sectional network was inferred by means of Gaussian Markov random field estimation using graphical LASSO and the extended Bayesian information criterion (EBIC-LASSO), and central symptoms of BED were identified by means of the strength c…

Nutrition and Dieteticslcsh:RC435-571MetacognitionInterpersonal communicationEmotion dysregulationmedicine.diseaseImpulse controlPsychotherapyBehavioral NeurosciencePsychiatry and Mental healthEating disordersBinge-eating disorderBinge eating disorderlcsh:PsychiatrymedicineNetwork analysisBinge severityPsychologyCentralityMetacognitionResearch ArticleNetwork analysisClinical psychologyPsychopathologyJournal of Eating Disorders
researchProduct

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

2021

Not Available

OncologyMalechronic B cell leukemiachronic lymphocytic leukemia; ibrutinib; 4-factor score; prognosis.Datasets as TopicSeverity of Illness Indexchemistry.chemical_compoundPiperidinesRetrospective analysisMulticenter Studies as TopicChronicLeukemiaHematologyMiddle AgedPrognosisLymphocyticProgression-Free SurvivalIbrutinibFemalemedicine.medical_specialtyreal-word studyFactor scoreAntineoplastic AgentsAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival AnalysisRisk AssessmentNOibrutinibInternal medicineSeverity of illnessmedicineHumansProgression-free survivalProtein Kinase InhibitorsSurvival analysisAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelAdenineB-CellReproducibility of ResultsRetrospective cohort studyAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Survival Analysis; Severity of Illness IndexLeukemia Lymphocytic Chronic B-CellSurvival AnalysisSettore MED/15 - MALATTIE DEL SANGUEchemistrybusinesschronic lymphocytic leukaemiaFollow-Up Studies
researchProduct

Biomarkers for Prognosis and Treatment Response in COVID-19 Patients

2021

During a severe infection such as coronavirus disease 2019 (COVID-19), the level of almost all analytes can change, presenting a correlation with disease severity and survival; however, a biomarker cannot be translated into clinical practice for treatment guidance until it is proven to have a significant impact. Several studies have documented the association between COVID-19 severity and circulating levels of C-reactive protein (CRP) and interleukin-6, and the accuracy of the CRP level in predicting treatment responses has been evaluated. Moreover, promising findings on prothrombin and D-dimer have been reported. However, the clinical usefulness of these biomarkers in COVID-19 is far from …

OncologyTreatment responsemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Clinical BiochemistryPredictive valueReview Articlemacromolecular substances030204 cardiovascular system & hematologySeverity of Illness IndexSeverityGeneral Laboratory MedicineFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineDisease severityInternal medicineSeverity of illnessHumansMedicine030212 general & internal medicineInterleukin 6biologyInterleukin-6SARS-CoV-2business.industryBiochemistry (medical)C-reactive proteinCOVID-19General MedicinePrognosisCoronavirusClinical PracticeMicroRNAsC-Reactive Proteinbiology.proteinBiomarker (medicine)businessBiomarkersAnnals of Laboratory Medicine
researchProduct

Breakthrough pain in oncology: A longitudinal study

2010

Abstract Context Existing studies on breakthrough pain (BP) have reported different prevalence rates because of different settings, populations, and assessment methods. These studies have used cross-sectional designs, and the relationship of BP with analgesic treatment has not been evaluated. Objectives The aim of this study was to longitudinally assess BP in cancer patients admitted to oncology units. Methods A consecutive sample of patients admitted to oncology centers was selected. At admission (T0), three months after admission (T3), and six months after admission (T6), data on background pain and BP were recorded. BP was assessed in terms of its intensity, duration, number of episodes,…

Oncologybreakthrough pain; Cancer pain; epidemiology; oncology; Acute Disease; Aged; Analgesics; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasms; Pain; Severity of Illness Index; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous)Malemedicine.medical_specialtyLongitudinal studyBreakthrough PainAnalgesicPrevalencePainContext (language use)Severity of Illness Indexlongitudinal study; breakthrough pain; cancer patientsInternal medicineNeoplasmsEpidemiologymedicineHumansLongitudinal StudiesStage (cooking)Cancer painGeneral NursingNursing (all)2901 Nursing (miscellaneous)AgedAnalgesicsbusiness.industrylongitudinal studyMiddle Agedbreakthrough painTreatment OutcomeAnesthesiology and Pain MedicineoncologyAcute DiseaseepidemiologyFemaleNeurology (clinical)cancer patientsbusinessCancer pain
researchProduct